



# Biotech Daily

Friday June 21, 2013

*Daily news on ASX-listed biotechnology companies*

- \* ASX, BIOTECH DOWN: PRIMA UP 15%, CIRCADIAN DOWN 14%**
- \* FEDERAL GOVERNMENT \$130m INDUSTRY COLLABORATION FUND OPENS**
- \* UNIQUEST APPOINTS DR DEAN MOSS CEO; MANAGEMENT CHANGES**
- \* LBT REQUESTS 'JOINT VENTURE' TRADING HALT**

## MARKET REPORT

The Australian stock market fell a further 0.41 percent on Friday June 21, 2013 with the S&P ASX 200 down 19.6 points to 4,738.8 points.

Ten of the Biotech Daily Top 40 stocks were up, 15 fell, 11 traded unchanged and four were untraded.

Prima was the best, up 0.9 cents or 14.75 percent to seven cents with 6.3 million shares traded, followed by Allied Health up 10.4 percent to 5.3 cents with 15.5 million shares traded.

Starpharma climbed seven percent; GI Dynamics was up five percent; Reva and Sirtex were up more than three percent; Heartware and Living Cell rose more than two percent; Alchemia and Nanosonics were up more than one percent; with CSL and Resmed up by less than one percent.

Circadian led the falls, down four cents or 13.8 percent to 25 cents with 12,500 shares traded.

Antisense lost 9.1 percent; Osprey fell 6.7 percent; Atcor, Bionomics, Impedimed and Viralytics were down five percent or more; Cellmid, Patrys and Tissue Therapies were all down 3.85 percent; Mesoblast and Psivida shed more than two percent; Acrux and Cochlear were down more than one percent; with Medical Developments and QRX down by less than one percent.

## FEDERAL GOVERNMENT

Businesses and research organizations within Industry Innovation Precincts can apply for Industry Collaboration Fund grants ranging from \$100,000 to \$10 million.

A media release from the Minister for Innovation Greg Combet said the Industry Collaboration Fund Program “would facilitate new collaborations and support projects that address market, technology and supply chain opportunities through the Industry Innovation Precincts”.

The media release said that the program’s guidelines had been released ahead of the opening of Round 1 on July 1, 2013, with funding rounds expected to be held twice a year. The media release said the program was “a key element of the \$500 million Industry Innovation Precincts initiative established under the Australian Government’s \$1 billion Plan for Australian Jobs” and the \$130 million Fund would offer grants ranging from \$100,000 to \$10 million with an annual investment of up to \$50 million a year by 2016-’17. “Projects supported under the Industry Collaboration Fund program will have potential to generate significant benefits, innovative practices and develop world-class commercial activity,” Mr Combet said.

The media release said that the first two Industry Innovation Precincts, Manufacturing and Food would begin in July and be eligible to apply for funding in Round 1.

Last week Mr Combet announced the 11-member board of the Manufacturing Precinct, which included four biotechnology-related representatives (BD: Jun 14, 2103).

The Federal Government said that up to eight remaining Precincts would be selected from industry-led proposals.

The media release said that Round 1 applications close on July 12, 2013, with more information on the program and guidelines at: <http://www.aussiejobs.innovation.gov.au/iip>.

## UNIQUEST

The University of Queensland’s commercialization company Uniquet has appointed Dr Dean Moss as its chief executive officer.

Uniquet said that Dr Moss joined its technology commercialization division in 2005 as the general manager responsible for leadership, business development and management of the company’s life sciences activities and had been acting chief executive officer since February 2013.

The organization said that Dr Moss had been the managing director or a senior manager in health and biotechnology companies including Agen Biomedical, Binax, Launch Diagnostics, Amrad Biotech, Amrad ICT, United Drug and his own start-up business in the UK, York Medical Technologies.

Uniquet said that Dr Moss assisted in raising more than \$75 million of venture investment and has held chair and director roles with Uniquet start-up companies including Coridon, Pepfactants, Q-Pharm and Vaxxas.

Uniquet said that Dr Moss assisted the board in developing a new strategy and has led its implementation, moving the organization into two businesses – intellectual property commercialization and expertise commercialization.

According to his LinkedIn page, Dr Moss holds a Bachelor of Science and a Masters of Philosophy in biochemistry from Griffith University and a Doctorate of Philosophy in medicine from the University of Queensland.

Uniquet said that Dr Judy Halliday had been appointed senior director of science, Dr Mark Ashton senior director of health and Dr Craig Belcher senior director of industry engagement.

Corporate development manager Leanne Wyvill has left the organization.

### LBT INNOVATIONS

LBT has requested a trading halt “pending an announcement of a proposed joint venture”. Trading will resume on June 25, 2013 or on an earlier announcement.  
LBT last traded at six cents.